Gilead Sciences Inc. (Nasdaq: GILD) has closed its acquisition of Tubulis GmbH for a total potential consideration of $5 billion, significantly expanding its capabilities in the highly competitive oncology market with a new class of cancer-killing drugs. The deal for the private, Germany-based biotech strengthens Gilead’s pipeline with next-generation antibody-drug conjugate (ADC) technology designed for more precise tumor targeting.
"Our two-year collaboration with Tubulis gave us strong conviction in their team, their programs and their technologies," Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, said. "We will now combine our strengths in service of providing new options for some of the most challenging forms of disease."
Under the terms, Gilead paid $3.15 billion in cash upfront, with an additional $1.85 billion tied to contingent milestone payments. The acquisition brings in Tubulis's lead clinical programs, TUB-040, a NaPi2b-targeting ADC for ovarian and lung cancer, and TUB-030, which is aimed at a variety of solid tumors.
The move represents a major investment in Gilead's long-term oncology strategy, building on the growth of its existing cancer drug, Trodelvy. However, the cost of this and other recent acquisitions will create a significant drag on near-term profitability. Gilead's management noted the Tubulis deal is part of a series of transactions expected to result in a non-GAAP loss per share for the full year 2026, driven by approximately $11.5 billion to $11.8 billion in upfront research and development charges.
Tubulis's Next-Generation ADC Platform
The core of the acquisition is Tubulis’s proprietary platform for developing ADCs, which are engineered to deliver potent chemotherapy payloads directly to cancer cells while minimizing damage to healthy tissue. The technology allows for a higher, more stable drug-to-antibody ratio, potentially leading to more durable anti-tumor activity and improved safety profiles compared to earlier ADCs.
The lead asset, TUB-040, has already shown promising anti-tumor activity and a manageable safety profile in early studies for platinum-resistant ovarian cancer. It is designed to attach eight topoisomerase-I inhibitor payloads to a single antibody, a design intended to maximize cancer-cell killing.
A Strategic Shift Amid Deal-Related Costs
Gilead's acquisition of Tubulis is the latest in a series of deals aimed at transforming the company into a major oncology player, diversifying beyond its traditional strength in HIV therapies. Sales of its flagship ADC, Trodelvy, climbed 37% year-over-year to $402 million in the first quarter of 2026, underscoring the potential of the ADC market.
While strategically sound, the cost of this expansion is substantial. The upfront payment for Tubulis, along with acquisitions of Arcellx and Oral Medicines, will swing Gilead to a projected full-year non-GAAP loss per share of between $0.65 and $1.05. Excluding these deal-related costs, the company guided for a non-GAAP EPS between $8.45 and $8.85, highlighting an approximate $9.50 per-share impact from its M&A activities.
This article is for informational purposes only and does not constitute investment advice.
